• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶剂/去污处理血浆中朊病毒减少对止血变量的影响。

The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables.

机构信息

Haemostasis Research Unit, Department of Haematology, University College London, London, UK.

出版信息

Vox Sang. 2010 Oct;99(3):232-8. doi: 10.1111/j.1423-0410.2010.01346.x.

DOI:10.1111/j.1423-0410.2010.01346.x
PMID:20840338
Abstract

BACKGROUND

Octapharma PPGmbH has recently modified its manufacturing process for solvent/detergent-treated plasma to incorporate a prion reduction step, in which a 3 log reduction has been demonstrated. The current study was undertaken to assess the impact of this procedure on haemostatic variables in the new product OctaplasLG in comparison with standard Octaplas.

METHODS

Production batches of standard Octaplas (n=4) and OctaplasLG (n=16) were assessed for levels of coagulation factors, physiological protease inhibitors, markers of activation and procoagulant microparticles. Global haemostasis was assessed by a thrombin generation test (TGT) and rotational thromboelastometry (ROTEM).

RESULTS

Mean levels of factors: II, V, VII, IX, X, XI, XII and XIII, VWF:Ag, antithrombin, protein C and free protein S were all >75 u/dl. ADAMTS-13 activity levels were normal. Factor VIII and VWF:RCo were >55 u/dl. TGT and ROTEM were similar in both preparations, and microparticles were present at negligible levels. Two units of OctaplasLG had slightly elevated levels of Prothrombin Fragments 1+2, but D-Dimer and thrombin-antithrombin complexes were normal in all batches.

CONCLUSION

These studies indicate that the affinity chromatography procedure used in OctaplasLG does not appear to adversely affect the proven haemostatic quality of Octaplas, while offering a selective reduction in the concentration of pathological prion proteins.

摘要

背景

奥克特珐玛 PPGmbH 最近修改了其溶剂/去污剂处理血浆的生产工艺,纳入了一个朊病毒减少步骤,该步骤已证明可减少 3 个对数。本研究旨在评估该程序对新产品 OctaplasLG 与标准 Octaplas 的止血变量的影响。

方法

评估了标准 Octaplas(n=4)和 OctaplasLG(n=16)的生产批次的凝血因子水平、生理蛋白酶抑制剂、激活标志物和促凝血微粒。通过凝血酶生成试验(TGT)和旋转血栓弹性测定法(ROTEM)评估整体止血功能。

结果

平均因子 II、V、VII、IX、X、XI、XII 和 XIII、VWF:Ag、抗凝血酶、蛋白 C 和游离蛋白 S 的水平均>75u/dl。ADAMTS-13 活性水平正常。因子 VIII 和 VWF:RCo 均>55u/dl。TGT 和 ROTEM 在两种制剂中均相似,微粒的存在水平可忽略不计。两个单位的 OctaplasLG 略有升高的凝血酶原片段 1+2 水平,但所有批次的 D-二聚体和凝血酶-抗凝血酶复合物均正常。

结论

这些研究表明,OctaplasLG 中使用的亲和层析程序似乎不会对 Octaplas 已证实的止血质量产生不利影响,同时选择性降低了病理朊病毒蛋白的浓度。

相似文献

1
The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables.溶剂/去污处理血浆中朊病毒减少对止血变量的影响。
Vox Sang. 2010 Oct;99(3):232-8. doi: 10.1111/j.1423-0410.2010.01346.x.
2
Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG.特定亲和配体在制药级溶剂/去污剂(S/D)处理血浆 OctaplasLG 生产过程中的引入对朊病毒的去除效果。
Vox Sang. 2009 Oct;97(3):226-33. doi: 10.1111/j.1423-0410.2009.01206.x. Epub 2009 Jun 22.
3
Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time.新型朊病毒蛋白(PrPSc)去除技术和减少溶剂/去污剂(S/D)处理时间后,OctaplasLG 许可血浆的生化质量。
Vox Sang. 2009 Oct;97(3):219-25. doi: 10.1111/j.1423-0410.2009.01190.x. Epub 2009 Apr 9.
4
Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing--results from animal bioassay studies.亲和配体层析法在 OctaplasLG® 生产过程中去除朊病毒感染性的研究——来自动物生物测定研究的结果。
Vox Sang. 2012 May;102(4):294-301. doi: 10.1111/j.1423-0410.2011.01563.x. Epub 2011 Nov 10.
5
The state of the art of removal of prion proteins in SD-FFP, by specific prion affinity chromatography and its impact on the hemostatic characteristics of the product.
Transfus Apher Sci. 2015 Apr;52(2):237-9. doi: 10.1016/j.transci.2015.02.012. Epub 2015 Feb 14.
6
Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.血浆蛋白制造工艺的朊病毒去除能力:来自 PPTA 成员公司的数据收集。
Transfusion. 2013 Sep;53(9):1894-905. doi: 10.1111/trf.12050. Epub 2012 Dec 17.
7
Investigation of prion removal/inactivation from chromatographic gel.从色谱凝胶中去除/灭活朊病毒的研究。
Vox Sang. 2006 Nov;91(4):301-8. doi: 10.1111/j.1423-0410.2006.00830.x.
8
Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing.解冻后48小时内溶剂/去污剂处理血浆和单供体新鲜冰冻血浆的稳定性
Transfus Apher Sci. 2005 Nov;33(3):257-67. doi: 10.1016/j.transci.2005.07.005. Epub 2005 Oct 3.
9
Update on pathogen reduction technology for therapeutic plasma: an overview.治疗性血浆病原体灭活技术的最新进展:概述
Transfus Apher Sci. 2006 Aug;35(1):83-90. doi: 10.1016/j.transci.2006.02.004. Epub 2006 Aug 24.
10
A biochemical quality study of a pharmaceutically licenced coagulation active plasma (Octaplas) thawed by the SAHARA-III dry tempering system compared to the regular use of a water bath.一项关于通过SAHARA-III干式回火系统解冻的药品许可凝血活性血浆(Octaplas)与常规使用水浴解冻相比的生化质量研究。
Vox Sang. 2008 Jan;94(1):48-55. doi: 10.1111/j.1423-0410.2007.00993.x. Epub 2007 Nov 16.

引用本文的文献

1
Frozen and freeze-dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality.冰冻及冻干溶剂/去污剂处理血浆:两种具有可比质量的不同药物制剂。
Transfusion. 2022 Dec;62(12):2621-2630. doi: 10.1111/trf.17139. Epub 2022 Oct 1.
2
Resuscitation of Endotheliopathy and Bleeding in Thoracic Aortic Dissections: The VIPER-OCTA Randomized Clinical Pilot Trial.胸主动脉夹层内皮病和出血的复苏:VIPER-OCTA 随机临床试点试验。
Anesth Analg. 2018 Oct;127(4):920-927. doi: 10.1213/ANE.0000000000003545.
3
Thawing of Pooled, Solvent/Detergent-Treated Plasma octaplasLG: Validation Studies Using Different Thawing Devices.
混合的、经溶剂/去污剂处理的八因子浓缩冷沉淀血浆(OctaplasLG)解冻:使用不同解冻设备的验证研究
Transfus Med Hemother. 2017 Apr;44(2):94-98. doi: 10.1159/000460302. Epub 2017 Mar 14.
4
Quality Assessment of Established and Emerging Blood Components for Transfusion.已确立和新兴输血用血液成分的质量评估
J Blood Transfus. 2016;2016:4860284. doi: 10.1155/2016/4860284. Epub 2016 Dec 14.
5
Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.应用于临床用血制品的病原体灭活技术的卫生技术评估。
Blood Transfus. 2016 Jul;14(4):287-386. doi: 10.2450/2016.0065-16.
6
Management of thrombotic thrombocytopenic purpura: current perspectives.血栓性血小板减少性紫癜的管理:当前观点
J Blood Med. 2014 Feb 5;5:15-23. doi: 10.2147/JBM.S46458. eCollection 2014.
7
Low incidence of hyperfibrinolysis and thromboembolism in 195 primary liver transplantations transfused with solvent/detergent-treated plasma.在195例接受溶剂/去污剂处理血浆输血的原位肝移植中,高纤溶和血栓栓塞的发生率较低。
Clin Med Res. 2014 Sep;12(1-2):27-32. doi: 10.3121/cmr.2013.1168. Epub 2014 Jan 10.